2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia

British Journal of Haematology

Volumn 99, Issue 2, 1997, Pages 352-357

  Tefferi, Ayalew ^a   Silverstein, Murray N ^b   Li, Chin Yang ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

2 chlorodeoxyadenosine; Hepatomegaly; Myelofibrosis with myeloid metaplasia; Splenectomy; Thrombocytosis

Indexed keywords

ALKALINE PHOSPHATASE; CLADRIBINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTINUOUS INFUSION; FATIGUE; FEMALE; HEPATOMEGALY; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTOSIS; LIVER SIZE; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PALLIATIVE THERAPY; PRIORITY JOURNAL; SPLENECTOMY; THROMBOCYTOSIS;

EID: 0030682516     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.3843198.x     Document Type: Article

References (18)

1. Avery, T.L., Rehg, J.E., Lumm, W.C., Harwood, F.C., Santana, V.M. & Blakley, R.L. (1989) Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Research, 49, 4972-4978.
2. Barosi, G., Ambrosetti, A., Buratti, A., Finelli, C., Liberato, N.L., Quaglini, S., Ricetti, M.M., Visani, G., Tura, S. & Ascari, E. (1993) Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia, 7, 200-206.
3. Berk, P.D., Wasserman, L.R., Fruchtman, S.M. & Goldberg, J.D. (1995) Treatment of polycythaemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. Polycythemia Vera and the Myeloproliferative Disorders (ed. by L. R. Wasserman, P. D. Berk and N. I. Berlin), pp. 166-194. Saunders, Philadelphia.
4. Beutler, E., Koziol, J.A., McMillan, R., Sipe, J.C., Romine, J.S. & Carrera, C.J. (1994) Marrow suppression produced by repeated doses of cladribine. Acta Haematologica, 91, 10-15.
5. Carrera, C.J., Terai, C., Lotz, M., Curd, J.G., Piro, L.D., Beutler, E. & Carson, D.A. (1990) Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo: a novel approach to immunosuppressive therapy. Journal of Clinical Investigation, 86, 1480-1488.
6. Carson, D.A., Wasson, D.B., Taetle, R. & Yu, A. (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood, 62, 737-743.
7. Heuck, G. (1879) Zwei Fälle von Leukämie mit eigenthümlichem Blut-resp. Knochenmarksbefund. Archiv für Pathologische Anatomie, 78, 475-496.
8. Liliemark, J., Albertioni, F., Hassan, M. & Juliusson, G. (1992) On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology, 10, 1514-1518.
9. Petzer, A.L., Bilgeri, R., Zilian, U., Haun, M., Geisen, F.H., Pragnell, I., Braunsteiner, H. & Konwalinka, G. (1991) Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood, 78, 2583-2587.
10. Raskind, W.H. & Fialkow, P.J. (1987) The use of cell markers in the study of human hematopoietic neoplasia. Advances in Cancer Research, 49, 127-167.
11. Reilly, J.T. (1994) Pathogenesis of idiopathic myelofibrosis: present status and future directions. British Journal of Haematology, 88, 1-8.
12. Santana, V.M., Mirro, J., Jr, Kearns, C., Schell, M.J., Crom, W. & Blakley, R.L. (1992) 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukaemia. Journal of Clinical Oncology, 10, 364-370.
13. Saven, A., Foon, K.A. & Piro, L.D. (1994a) 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Annals of Internal Medicine, 121, 430-432.
14. Saven, A., Piro, L.D., Lemon, R.H., Figueroa, M.L., Kosty, M., Ellison, D.J. & Beutler, E. (1994b) Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukaemia after 2-chlorodeoxyadenosine. Cancer, 73, 2953-2963.
15. Silverstein, M.N. (1975) Agnogenic Myeloid Metaplasia. Publishing Sciences Group, Acton, Massachusetts.
16. Silverstein, M.N. & ReMine, W.H. (1979) Splenectomy in myeloid metaplasia. Blood, 53, 515-518.
17. Tallman, M.S. & Hakimian, D. (1995) Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood, 86, 2463-2474.
18. Tefferi, A., Silverstein, M.N. & Noel, P. (1995) Agnogenic myeloid metaplasia. Seminars in Oncology, 22, 327-333.